Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.J.
Right arrow Articles by Simoons, M.L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van de Werf, F.J.
Right arrow Articles by Simoons, M.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Managing ST elevation myocardial infarction

F.J. Van de Werf*,1, E.M. Antman2 and M.L. Simoons3

a University Hospital Gasthuisberg, Leuven, Belgium
b Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA
c Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands

* Correspondence: Frans J. Van de Werf, MD, PhD, Professor and Chairman, Dienst Cardiologie, UZ Gasthuisberg, Herestraat, 49, 3000 Leuven, Belgium.

Abstract

Fibrinolytic therapy has long been an important component of the treatment of patients with ST-elevation myocardial infarction (STEMI). Several new treatment strategies are currently being developed to improve the treatment of STEMI. These strategies include the development of new fibrinolytic agents that possess longer half-lives or increased fibrin specificity as compared with streptokinase or alteplase; combining fibrinolytic therapy with recently developed antiplatelet medications; and substitution of low-molecular weight heparins or other newer thrombin inhibitors for unfractionated heparin to improve the safety, convenience and efficacy of antithrombotic therapy.

Key Words: Antiplatelet agents • fibrinolytic drugs • low-molecular-weight heparin • myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.